<table>
<thead>
<tr>
<th>Recipient</th>
<th>Cancer Center</th>
<th>Specialty</th>
<th>Disease Focus</th>
<th>CCITLA Activities</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian C. Baumann, MD</td>
<td>Alvin J. Siteman Cancer Center, Washington University School of Medicine</td>
<td>radiation oncology</td>
<td>genitourinary (GU) cancers</td>
<td>conduct radiation therapy clinical trials in GU cancers, mentorship of trainees and junior faculty</td>
</tr>
<tr>
<td>Daniel V. T. Catenacci, MD</td>
<td>University of Chicago Comprehensive Cancer Center</td>
<td>medical oncology</td>
<td>gastrointestinal (GI) cancers</td>
<td>building NCI clinical trial capacity, developing a precision-oncology education program</td>
</tr>
<tr>
<td>Kristen K. Ciombor, MD, MSCI</td>
<td>Vanderbilt-Ingram Cancer Center, Vanderbilt University</td>
<td>medical oncology</td>
<td>gastrointestinal (GI) cancers</td>
<td>biomarkers of colon cancer, mentorship, develop a clinical trial design seminar series</td>
</tr>
<tr>
<td>Bree R. Eaton, MD</td>
<td>Winship Cancer Institute of Emory University</td>
<td>radiation oncology</td>
<td>pediatric &amp; adult brain CNS cancers</td>
<td>expand clinical trials and increase trial accrual at Winship, develop an AYA working group</td>
</tr>
<tr>
<td>Zeynep Eroglu, MD</td>
<td>H. Lee Moffitt Cancer Center &amp; Research Institute</td>
<td>medical oncology</td>
<td>melanoma and skin cancers</td>
<td>build upon her clinical trial and biomarker research, mentorship of trainees and junior faculty</td>
</tr>
<tr>
<td>Joseph W. Kim, MD</td>
<td>Yale Cancer Center, Yale University School of Medicine</td>
<td>medical oncology</td>
<td>genitourinary (GU) cancers</td>
<td>launch bladder preservation program, increase clinical trials access to minority &amp; underserved groups, mentorship</td>
</tr>
<tr>
<td>Mark V. Mishra, MD</td>
<td>Marlene &amp; Stewart Greenebaum Comprehensive Cancer Center, University of Maryland</td>
<td>radiation oncology</td>
<td>CNS &amp; genitourinary (GU) cancers</td>
<td>expand UMGCCC’s clinical trial activities, focus on comparative effectiveness of new &amp; complex radiation technologies</td>
</tr>
<tr>
<td>Zahi I. Mitri, MD, MS</td>
<td>OHSU Knight Cancer Institute, Oregon Health &amp; Science University</td>
<td>medical oncology</td>
<td>breast cancers</td>
<td>develop and lead innovative early phase breast cancer trials</td>
</tr>
<tr>
<td>Alison M. Schram, MD</td>
<td>Memorial Sloan Kettering Cancer Center</td>
<td>medical oncology</td>
<td>gynecologic cancers</td>
<td>novel strategies to fight cancer through early-phase clinical trials</td>
</tr>
<tr>
<td>Nataliya V. Uboha, MD, PhD</td>
<td>Carbone Cancer Center, University of Wisconsin</td>
<td>medical oncology</td>
<td>gastrointestinal (GI) cancers</td>
<td>build &amp; lead Developmental Therapeutics Program and Basket Research Group</td>
</tr>
</tbody>
</table>

For a list of past CCITLA awardees, please visit: [http://www.cancer.gov/about-nci/organization/ccct/funding/ccitla](http://www.cancer.gov/about-nci/organization/ccct/funding/ccitla)
2021 NCI Cancer Clinical Investigator Team Leadership Award Recipients

Brian C. Baumann, MD
Alvin J. Siteman Cancer Center
Washington University School of Medicine

Dr. Brian Baumann is an Assistant Professor of radiation oncology at Washington University in St. Louis, where he also serves as Chief of Genitourinary Radiation Oncology. He completed his undergraduate education at Princeton University and medical school and residency at the University of Pennsylvania, where he was the recipient of an NIH T-32 Radiobiology training grant. He joined the faculty at Washington University in 2017. Dr. Baumann has distinguished himself as a leader in the field of genitourinary (GU) cancer and proton therapy and works collaboratively to improve cancer care and research at the Siteman Cancer Center as a team leader. He has published results from a randomized phase III trial of adjuvant therapy after radical cystectomy as senior and corresponding author that changed the treatment algorithm in the NCCN bladder guidelines and has published the definitive comparative effectiveness study of proton vs. photon chemo-radiotherapy. At Washington University, the genitourinary radiation oncology division that Dr. Baumann leads has distinguished itself as the top accruing center for NRG Oncology cooperative group trials.

As a recipient of the Cancer Clinical Investigator Team Leadership Award (CCITLA), Dr. Baumann will work to improve outcomes for GU cancer patients by developing and conducting several single and multi-institutional trials in the field of prostate and bladder cancer. He is developing an NRG Oncology cooperative group phase III randomized trial testing the efficacy and toxicity of a focal radiation boost dose to the gross disease in the prostate for men with unfavorable intermediate risk localized prostate cancer. Dr. Baumann has been named as Principal Investigator (PI) by the NRG GU committee to develop this trial concept as a companion trial to the NRG GU 010 phase III trial for which he serves as radiation oncology co-chair. Dr. Baumann will serve as the international PI for a multi-center trial of adaptive radiation therapy for definitive treatment of bladder cancer as well as a single-institution trial of adaptive prostate stereotactic body radiation therapy. He will continue his proton therapy clinical research, his translational research investigating biomarkers in bladder cancer and radiopharmaceuticals for the treatment of prostate cancer. Dr. Baumann will continue his mentorship of trainees and junior faculty and his leadership roles in the cancer center and on national cancer committees, including the NCI Bladder Cancer Task Force, NCCN Guidelines committee, the NRG GU Committee and Proton Committee, and the National Association for Proton Therapy physician advisory council and Board of Directors.
Daniel V. T. Catenacci, MD

University of Chicago Medical Center & Biological Sciences

Daniel Catenacci, MD, is an adult gastrointestinal medical oncologist and director of the gastrointestinal oncology program at the University of Chicago Medicine in Chicago, IL. He also serves as the assistant director of translational research in the Comprehensive Cancer Center. Dr Catenacci received his medical degree from Wayne State University School of Medicine in Detroit, MI. He completed his internship and residency at the University of California Los Angeles Health in Los Angeles, CA, and his fellowship at the University of Chicago Medicine. Dr Catenacci is board certified in medical oncology. He previously received a K23 career development award from the National Cancer Institute.

Dr Catenacci is an active basic and clinical researcher, focusing on the treatment of gastroesophageal (esophagus, gastroesophageal junction, and stomach) cancers. His bench-to-bedside translational research has an overarching goal to validate and improve personalized diagnostics, treatment, immunotherapy, and precision medicine for gastroesophageal cancer and other GI cancers. A major focus of his research is on the quantification of tumor genetic molecular heterogeneity both between individuals with gastroesophageal cancer, but importantly also within a given individual within one tumor site, and from one tumor site to another, and how this impacts personalized targeted therapeutic approaches. Additionally, Dr Catenacci designs and executes novel clinical trials to implement treatment strategies based on these laboratory and clinical discoveries.

Dr Catenacci serves as an associate editor for the Journal of American Medical Association Network Open (JAMA Netw Open) and is on the editorial boards of the Journal of Clinical Oncology Precision Oncology (J Clin Oncol PO), Cancer, and Cancers.

Funding support provided by this award will facilitate the implementation of two main projects: 1) Building out NCI clinical trial capacity at University of Chicago Medicine Comprehensive Cancer Center (UCCC) network affiliate sites; and 2) Developing a precision-oncology education program within the UCCC for fellows in medical oncology, as well as other disciplines in which precision and immuno-oncology-related medical issues are of relevance.
Kristen K. Ciombor, MD, MSCI

Vanderbilt-Ingram Cancer Center
Vanderbilt University

Dr. Kristen K. Ciombor is an Associate Professor in the Division of Hematology/Oncology within the Department of Internal Medicine at the Vanderbilt University Medical Center. She completed her undergraduate training with honors in biochemical sciences from Harvard College in 2001 and received her medical degree from the University of Miami Miller School of Medicine in 2005. She completed her internal medicine residency and chief residency at the University of Miami/Jackson Medical Center/Miami VA Medical Center in Miami, FL. She then moved to Nashville, TN to complete her fellowship training in hematology/oncology at Vanderbilt, where she was named both an T32 and K12 scholar and graduated with a Master of Science in Clinical Investigation. Prior to joining the Vanderbilt faculty in 2017, Dr. Ciombor was an Assistant Professor of Internal Medicine in the Division of Medical Oncology at the Ohio State University. She was also a recipient of the National Institutes of Health (NIH) Loan Repayment Program Award.

A board-certified medical oncologist, Dr. Ciombor specializes in the treatment of patients with gastrointestinal (GI) cancers. Her research involves the design and implementation of clinical trials for GI malignancies, and colorectal cancer (CRC) in particular, and she leads multiple national investigator-initiated clinical trials in this space. She has a strong research interest in the genomics of colorectal cancer and translational medicine and has received competitive funding for her preclinical and clinical work in the role of the fibroblast growth factor receptor (FGFR) pathway in CRC. She is an integral member of the Vanderbilt-Ingram Cancer Center’s (VICC) Gastrointestinal Specialized Program of Research Excellence (GI SPORE), the Eastern Cooperative Oncology Group (ECOG), the National Comprehensive Cancer Network’s (NCCN) Colorectal/Anal/Small Bowel Guidelines Panel, the International Rare Cancers Initiative (IRCI) Anal Cancer Working Group, the Academic GI Cancer Consortium (AGICC), the Colorectal Cancer Alliance Biomarker Think Tank Advisory Committee, of which she co-chairs, and the Academic and Community Cancer Research United (ACCRU), of which she serves on the board of directors.

As a recipient of the 2021 Cancer Clinical Investigator Team Leadership Award, Dr. Ciombor will continue to impact the field of gastrointestinal medical oncology through the design, implementation, and analysis of innovative colorectal cancer clinical trials. She is the national principal investigator of EA2201, a phase II study of neoadjuvant nivolumab and ipilimumab and short-course radiation in patients with MSI-H/dMMR locally advanced rectal adenocarcinoma. This exciting study will investigate the clinical efficacy of immunotherapy and radiation in this unique patient population, as well as analyze and monitor circulating tumor DNA and minimal residual disease throughout treatment and in post-treatment surveillance. She is also designing a phase I/II clinical trial of cabozantinib and panitumumab for patients with RAS wild-type metastatic colorectal cancer on the basis of novel preclinical evidence obtained in the Vanderbilt laboratories of collaborators Drs. Robert Coffey and Bhuminder Singh demonstrating that resistance to anti-epidermal growth factor receptor (EGFR) treatment can be partially conferred by MET/RON activation. As part of her passion for excellent clinical trial design and mentorship, she will develop a seminar series at the Vanderbilt-Ingram Cancer Center for trainees exploring clinical trial design, VICC-specific initiatives and resources, and encouragement in the development of clinical research careers in academic oncology.
Dr. Bree Eaton is an Assistant Professor of Radiation Oncology at Emory University School of Medicine and Pediatric Medical Director of the Emory Proton Therapy Center. Dr. Eaton is an active member of Winship Cancer Institute and the Children’s Healthcare of Atlanta Aflac Blood Disorders and Cancer Center, where she specializes in the treatment of brain and spine tumors, and pediatric malignancies, with a particular focus in the use of proton therapy.

Dr. Eaton graduated summa cum laude from Denver University with a BS in Cognitive Neuroscience and completed medical school at the Medical University of South Carolina where she was elected in the Alpha Omega Alpha medical honors society. Dr. Eaton completed her Radiation Oncology Residency at Emory University in 2014 where she was selected to serve as chief resident during her final year. Dr. Eaton then went on to complete a fellowship in Pediatric Proton Radiotherapy and Clinical Research at Massachusetts General Hospital/Harvard University Medical School in Boston, MA before returning to Emory as faculty in August 2015.

Her research focus lies in developing clinical trials designed to test innovative radiotherapy techniques or dose-fractionation schedules intended to improve clinical outcomes and minimize treatment associated toxicity for pediatric and adult brain tumor patients. Dr. Eaton is extensively involved in clinical trials at Winship, where she is the principal investigator of five investigator-initiated clinical trials for pediatric and adult brain tumor patients, the site principle investigator for multiple NCI funded cooperative group clinical trials, and an associate investigator on numerous others. She is an integral member of Winship’s Clinical and translational Research Committee (CTRC), providing radiation oncology expertise in the scientific review of all oncology related clinical trials in preparation for submission to the institutional review board. On a national level, Dr. Eaton is an active member in multiple national committees of NRG Oncology and the Children’s Oncology Group (COG) and Pediatric Brain Tumor Consortium (PBTC), including the NRG Oncology Patient Centered Outcomes Committee, the COG Brain Tumor Committee, Bone Tumor Committee and the Adolescent and Young Adult (AYA) Cancer Committee and the PBTC Radiation Oncology Committee.

Dr. Eaton’s planned activities for the CCITLA award include leading process improvement initiatives designed to expand clinical trials and increase trial accrual at Winship, as well as further develop her own protocol concepts at the national level. Specifically, Dr. Eaton plans to develop an Adolescent and Young Adult (AYA) working group with representatives from both Children’s Healthcare of Atlanta and Winship Cancer Institute of Emory University to expand clinical trial options and increase accrual for the pediatric and young adult cancer populations. Dr. Eaton will join the ECOG-ACRIN brain tumor committee and regularly attend the ECOG-ACRIN, NRG Oncology, COG and PBTC annual and semi-annual meetings in effort to expand the NCI funded brain tumor trials available at Winship. She will also lead an initiative within the Winship Brain Tumor program multi-disciplinary clinic (MDC) to promote NCI Brain Tumor clinical trial accrual through a redesigned process of prompt clinical trial screening, multi-disciplinary review, patient education and consent. She will join Winship’s Data Safety Monitoring Committee as the radiation oncology representative to help ensure appropriate conduct of clinical trials involving radiotherapy. Finally, Dr. Eaton will further develop her own study concepts for NCI-funded trials through the NTCN networks on the following topics: Hypofractionated Radiosurgery for Large Brain Metastases, Proton Therapy for Pediatric High-grade Glioma and Dose Escalated Radiotherapy for Localized Unresectable Ewing Sarcoma.
Zeynep Eroglu, MD

H. Lee Moffitt Cancer Center & Research Institute

Dr Eroglu is an Assistant Member in the Department of Cutaneous Oncology at Moffitt Cancer Center and an Assistant Professor at the University of South Florida for the past 5 years. She graduated from the David Geffen School of Medicine at UCLA, finished her internal medicine residency at University of California, Irvine and completed her hematology/oncology fellowship at the City of Hope/Harbor-UCLA program.

Dr Eroglu is a clinical investigator, focusing on translational and clinical research in the study of skin cancers including melanoma. Her clinical focus is on treating patients with advanced melanoma and other skin cancers such as basal cell, squamous cell, and Merkel cell carcinomas, and developing and participating in clinical trials. Her scientific interest involves clinical and translational research in targeted therapies and combination immunotherapies, along with development of biomarkers to predict treatment outcomes and personalized treatment strategies for patients. She has published first-authors manuscripts in journals such as *Nature* and *Clinical Cancer Research* and has collaborated extensively with colleagues from major cancer centers around the world in numerous translational and clinical projects.

Dr Eroglu has also written several investigator-initiated clinical trial protocols that have successfully completed accrual, and also is the principal investigator of six current investigator-initiated trials at Moffitt, including two combination studies in treatment-refractory melanoma, a neoadjuvant melanoma trial with treatment decisions based on pathologic response, a combination triplet regimen in BRAF-mutant melanoma based on mathematical modeling, and a trial of a novel agent in treatment-refractory squamous cell carcinomas. She is also the national principal investigator and Study Chair of an NCI SWOG group trial in melanoma brain metastases, (SWOG S2000).

As a recipient of the Cancer Clinical Investigator Team Leadership Award, Dr. Eroglu will move forward in conducting her recently activated and upcoming investigator-initiated studies in advanced skin cancers, continue her involvement in various scientific committees, and continue mentoring of fellows and students. She also plans to build upon her clinical trial and biomarker research, including expanding the S2000 trial’s translational aims, and in further developing successful personalized clinical trials in skin cancers based on mathematical oncology.
Dr. Joseph W. Kim is an Associate Professor of Medicine (Medical Oncology) at Yale School of Medicine, where he specializes in prostate cancer, bladder cancer and other genitourinary (GU) cancers and in phase I drug development in advanced solid tumors.

He earned his MD from Wake Forest University School of Medicine and completed his Internal Medicine residency program at Emory University and Medical Oncology fellowship program at National Cancer Institute of NIH. He received a Young Investigator Award from Conquer Cancer Foundation of ASCO. Dr. Kim leads several clinical and translational research programs in Phase I and GU Cancer Programs at Yale Cancer Center. Dr. Kim serves as a study chair for three ETCTN clinical trials and a site Principal Investigator (PI) of multiple ETCTN and NCTN clinical trials in prostate and bladder cancer as well as industry sponsored trials. Dr. Kim is an active member of SWOG GU Organ Site Committee and Prostate Cancer subcommittee and ETCTN’s Disease Focused Clinical Investigators for genitourinary malignancies.

As a recipient of 2021 Cancer Clinical Investigator Team Leadership Award, Dr. Kim will co-lead the effort to launch burgeoning Yale’s Bladder Preservation Program with his urology and radiation oncology colleagues. Dr. Kim will focus on building clinical research pathway not only to boost the accrual to the NCI-funded interdisciplinary bladder preservation trial, but also to streamline the pathway for biospecimen banking and to design and conduct NCI funded, high impact clinical trials for bladder cancer. As a core faculty of Yale Hematology/Oncology Fellowship Program, Dr Kim will have ample opportunities to mentor trainees to develop hypothesis-driven clinical trials from this Bladder Program. Finally, with recognition of lack of awareness and limited access to clinical trials amongst racial/ethnic minorities in the state of Connecticut, Dr. Kim will co-lead an innovative phase 1 trial operation model that will increase access to the racial/ethnic minorities. Dr. Kim also participates in Yale Cultural Ambassador Program to provide seminar series to African American communities in New Haven County and beyond to increase the awareness of clinical trials and prostate cancer.
2021 NCI Cancer Clinical Investigator Team Leadership Award Recipients

Mark V. Mishra, MD
Marlene & Stewart Greenebaum Comprehensive Cancer Center
University of Maryland School of Medicine

Dr. Mark Mishra is an Associate Professor of Radiation Oncology at the University of Maryland School of Medicine. He also serves as the Director of Clinical Research for the University of Maryland Greenebaum Comprehensive Cancer Center (UMGCC) Department of Radiation Oncology and focuses on treating patients with tumors of the central nervous system and the genitourinary tract. Dr. Mishra is a graduate of the University of Cincinnati College of Medicine and completed his residency in Radiation Oncology at Thomas Jefferson University. He also completed a year-long clinical research fellowship in the NIH Clinical Research Training Program (CRTP) and completed the Program in Clinical Effectiveness at the Harvard T.H. Chan School of Public Health. In his role as Director of Radiation Oncology Clinical Research, Dr. Mishra oversees all clinical trial activities for Radiation Oncology at UMGCCC and at affiliated practices across the State of Maryland. Dr. Mishra also serves UMGCCC Voting-Member Contact Principal Investigator (PI) for NRG Oncology, and is the co-chair for the UMGCCC Clinical Research Committee.

Dr. Mishra’s research focus is centered on evaluating the comparative- and cost-effectiveness of new and complex radiation technologies such as proton beam therapy, as well as evaluating novel uses of radiation therapy alone or in combination with other therapies. Dr. Mishra previously received the American Society of Radiation Oncology (ASTRO) Comparative Effectiveness Grant and is the Comparative Effectiveness Co-Chair for two recently activated NCTN clinical trials (NRG BN009 and NRG CC009). He is the PI for several investigator-initiated trials at UMGCCC.

As a recipient of the 2021 CCITLA, Dr. Mishra’s work will focus on further expanding UMGCCC’s clinical trial activities. Dr. Mishra will focus on growing the clinical trial portfolio at UMGCCC affiliated community practice and the Baltimore Veteran Affairs Medical Center, while also working to identify (and address) any barriers to clinical trial accrual. He will also organize and lead a neuro-oncology clinical trials working group to further develop brain tumor clinical trial efforts at UMGCCC, with a focus on growing the number of multidisciplinary investigator-initiated clinical trial efforts. Dr. Mishra will also expand on his own clinical trial roles and responsibilities at UMGCCC, through efforts such as participating in the University of Maryland Baltimore IRB, and will also focus further developing his research efforts related to cost- and comparative effectiveness research.
Zahi I. Mitri, MD, MS

OHSU Knight Cancer Institute
Oregon Health & Science University

Dr. Zahi Mitri, MD is an Assistant Professor of Medicine in the Division of Hematology and Medical Oncology at the Oregon Health and Science University (OHSU) Knight Cancer Institute. Dr. Mitri is the Program Director for Breast Cancer and a member of the Knight Cancer Institute’s Translational Oncology Research Program. He is a medical oncologist specializing in breast cancer. Dr. Mitri completed his medical training at the American University of Beirut, Lebanon, and received his Internal Medicine training at Emory University Hospital in Atlanta, GA. He completed a Hematology and Medical Oncology Fellowship at the University of Texas MD Anderson Cancer Center, as well as a Master of Science in Clinical and Translational Sciences from the University of Texas Graduate School of Biomedical Sciences. Dr. Mitri joined the faculty of OHSU Knight Cancer Institute in 2016.

Dr. Mitri’s research focuses on conducting innovative clinical trials aimed at developing novel targeted and immuno-therapy combinations and biomarkers of sensitivity/resistance to advance the treatment of breast cancer. He has extensive experience in clinical and translational investigation as the Principal Investigator (PI) of multiple investigator-initiated trials and as an investigator on several NCTN and industry trials. Dr. Mitri is the Breast Cancer Clinical Lead for the Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) project, a Knight Cancer Institute Precision Oncology Program aimed at developing a robust biomarker platform to deliver personalized therapies and improve outcomes for breast cancer patients. In addition to these efforts, Dr. Mitri serves as the co-chair of the Knight Cancer Institute scientific review committee and is an active member of the SWOG Breast Cancer Committee, the SWOG Translational Medicine Breast Cancer Committee, and the SWOG Immunotherapeutic Committee. He also serves as the SWOG Early Investigator Representative on the NCI Breast Immuno-Oncology (BIO) Task Force.

As a recipient of the Cancer Clinical Investigator Team Leadership Award (CCITLA), Dr. Mitri will look to continue developing and leading innovative early phase breast cancer trials. These efforts will include: 1) Two trials examining novel combinations in metastatic triple negative breast cancer, 2) A phase 1 neoadjuvant targeted therapy in hormone receptor positive breast cancer, and 3) Two trials evaluating precision oncology approaches for metastatic breast cancer. The CCITLA will also allow Dr. Mitri to continue serving on institutional and national committees.
Alison M. Schram, MD
Memorial Sloan Kettering Cancer Center

Dr. Schram is a medical oncologist with a specific interest in clinical and translational research that focuses on developing novel, rational therapeutics through molecular targeting. Throughout her training Dr. Schram has been devoted to treating patients with cancer and studying the genetics of malignancy. Dr. Schram graduated from the University of Michigan in 2007 with a Bachelor of Science and attended the University of Pennsylvania medical school. While in medical school she participated in the Memorial Sloan Kettering Summer Fellowship Program during which she worked in the laboratory of Dr. Ross Levine and identified a genetic predisposition to myeloproliferative neoplasms (MPNs). Dr. Schram was later selected to be a Howard Hughes Medical Fellow and through this program spent a dedicated year in the laboratory studying MPNs. Dr. Schram subsequently went to Brigham and Women’s Hospital where she became fascinated with the intersection of genomics with patient care. She had the privilege of caring for many cancer patients on clinical trials and developed a strong appreciation for the process that allows the translation of laboratory observations to the clinic.

As a medical oncology fellow and now faculty at Memorial Sloan Kettering Cancer Center (MSKCC), Dr. Schram joined the Early Drug Development Service (EDD) and Gynecologic Medical Oncology Services where she is dedicated to the development of novel strategies to fight cancer through early-phase clinical trials. Dr. Schram has written and is the Principal Investigator (PI) on many EDD studies. Dr. Schram was also a member of Barry Taylor’s laboratory, which uses computational approaches to analyze tumor sequencing data to identify the somatic genomic abnormalities that mediate cancer development, progression, and treatment response or resistance. Dr. Schram’s translational work focuses on using novel strategies to identify mechanisms of treatment resistance to targeted therapy. She is passionate about leveraging tumor genomics to improve cancer treatments.

With the support of the CCITLA Dr. Schram plans to continue to focus on clinical trials, including two studies she is leading through the NCI. The first is an ETCTN biomarker-driven tumor-agnostic study in patients with tumors harboring PTEN or PIK3CB mutations. The second is a NCTN study of tazemetostat in patients with certain gynecologic tumors including ovarian clear cell carcinoma, an understudied orphan disease for which better treatments are necessary. Both trials include robust biospecimen correlative analyses and bring together multiple collaborators.

Ultimately, Dr. Schram wants to be a clinical investigator with a deep understanding of the biology of malignancy, and the ability to design and run clinical trials that further the treatment of cancer. She hopes to continue working with the NCI throughout her career.
Nataliya V. Uboha, MD, PhD

Carbone Cancer Center
University of Wisconsin

Dr. Uboha is an Associate Professor in the Hematology, Medical Oncology and Palliative Care Division at University of Wisconsin, Carbone Cancer Center (UWCCC). Dr. Uboha received her MD and PhD from Yale University in 2007. She subsequently completed a residency in internal medicine and a fellowship in hematology and medical oncology at Yale New Haven Hospital. She joined faculty at UWCCC in 2015. Dr. Uboha’s clinical interests include gastrointestinal (GI) cancers, with a particular emphasis on hepatobiliary and gastroesophageal cancers. Her research focuses on the development of early phase and biomarker based clinical trials for patients with gastrointestinal malignancies. She has significant clinical trial experience, serving as a principal investigator on multiple investigator-initiated, NCI sponsored, and industry sponsored studies.

In 2018, Dr. Uboha helped launch Basket Research Group, which has a specific concentration on biomarker-based basket studies. In spring 2021, she assumed a faculty leader role for Developmental Therapeutics Program, which is the largest program at the UWCCC, and which includes the UWCCC’s Phase I research group. Dr. Uboha also holds several leadership positions regionally and nationally. She co-chairs GI Working Group in Big 10 Cancer Research Consortium. She serves on the Upper GI Cancers Task Force in NCI as an ECOG-ACRIN representative. She is a member of NCCN committee for neuroendocrine tumors.

As a recipient of a 2021 Cancer Clinical Investigator Team Leadership Award, Dr. Uboha will continue to build and lead Developmental Therapeutics Program and Basket Research Group at UWCCC. CCITLA award will allow for protected time dedicated to administrative duties that are essential for successful operation of these research units. She will continue to focus on running biomarker based clinical studies across tumor types, with emphasis on expanding activation and improving access to NCI-funded clinical trials. This award will also support Dr. Uboha as she continues her work as a national chair for an ECOG-ACRIN clinical trial: Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EA2183). This study is currently enrolling patients in multiple sites in the United States. In addition, she will dedicate her time to mentoring junior faculty and support their engagement in clinical research at UWCCC.